CTSI Announcement
The overarching goal of the BU CTSI Pilot Grant Program is to help investigators explore and solve major challenges in translational science, especially those that address the special health problems of our urban communities, by developing and deploying new tools, methods, and processes to expedite clinical and translational research and discovery. Review the Full RFA Here.
New Product/Device Development
CTSI seeks to encourage the development and evaluation of
new products, devices, or drug targets that have commercial potential. While CTSI will support applicants at any stage of the development timeline, this mechanism is best suited to early feasibility studies and/or proof of concept. Applicants will be connected to institutional resources to support this process.
Eligibility
  • Applicants must have a primary faculty appointment at Boston University, and the research to be conducted must be based at Boston University, Boston Medical Center, or any of their affiliated hospitals and health centers.

  • Faculty with co-appointments at BU and BU/BMC affiliated institutions are also encouraged to apply. 

  • Recipients of previous CTSI awards are eligible to apply for awards to support new research projects, providing awards are at least two years apart.

  • Individuals from under-represented groups are highly encouraged to apply.

  • Applications from interdisciplinary teams of investigators are highly encouraged. Collaborations with investigators outside of the BU/BMC and affiliates are allowed, though justification should be provided. 
Available Funding
  • Direct costs up to $20,000 may be requested for applications with a single PI
  • Direct costs up to $50,000 may be requested for applications with 2 or more investigators comprising a credible research team (funding at this level will be subject to resource availability). Interdisciplinary teams comprised of investigators from different Sections, Departments, Schools, Institutions, or campuses will be prioritized. 

Application Due Date


  • Monday, September 6, 2021, at 5 p.m. EST